Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Cellectis S.A. - American Depositary Shares (NQ:CLLS)

3.420 UNCHANGED

Streaming Delayed Price Updated: 10:04 AM EDT, Aug 26, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	9,859
Open	3.440
Bid (Size)	3.380 (1,000)
Ask (Size)	3.420 (100)
Prev. Close	3.420
Today's Range	3.420 - 3.500
52wk Range	2.350 - 5.480
Shares Outstanding	45,484,310
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Cellectis Reports Financial Results for the Second Quarter 2026

August 06, 2026

From Cellectis Inc.

Via GlobeNewswire

Cellectis to Report Second Quarter Financial Results on August 6, 2026

July 30, 2026

From Cellectis Inc.

Via GlobeNewswire

Performance

YTD	-28.8%	-28.8%
1 Month	+18.3%	+18.3%
3 Month	-6.8%	-6.8%
6 Month	-14.1%	-14.1%
1 Year	+27.1%	+27.1%

More News

Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio

July 15, 2026

From ProLynx Inc.

Via GlobeNewswire

Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026

June 25, 2026

From Cellectis Inc.

Via GlobeNewswire

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

June 11, 2026

From Cellectis Inc.

Via GlobeNewswire

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

June 09, 2026

From Cellectis Inc.

Via GlobeNewswire

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline ↗

May 21, 2026

Via The Motley Fool

Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year ↗

May 21, 2026

Via The Motley Fool

Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026

May 20, 2026

From Cellectis Inc.

Via GlobeNewswire

Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress

May 12, 2026

From Cellectis Inc.

Via GlobeNewswire

Cellectis Reports Financial Results for the First Quarter 2026

May 11, 2026

From Cellectis Inc.

Via GlobeNewswire

Cellectis to Report First Quarter Financial Results on May 11, 2026

May 04, 2026

From Cellectis Inc.

Via GlobeNewswire

Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting

April 27, 2026

From Cellectis Inc.

Via GlobeNewswire

Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform

April 13, 2026

From Cellectis Inc.

Via GlobeNewswire

Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗

March 22, 2026

Via The Motley Fool

Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

March 12, 2026

From Cellectis Inc.

Via GlobeNewswire

Cellectis Announces 2026 Strategy and Catalysts

January 08, 2026

From Cellectis Inc.

Via GlobeNewswire

Traders are paying attention to the gapping stocks in Monday's session. ↗

December 29, 2025

Via Chartmill

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

December 15, 2025

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Cellectis Announces Arbitral Decision in Dispute with Servier

December 15, 2025

From Cellectis Inc.

Via GlobeNewswire

ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL

December 08, 2025

From Cellectis Inc.

Via GlobeNewswire

Why Cellectis Stock Is Trading Higher Today ↗

November 19, 2025

Via Benzinga

European ADRs Navigate Choppy Waters: Pharma Sector Shows Resilience Amidst Broader Market Volatility

November 19, 2025

Via MarketMinute

Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells

November 19, 2025

From Cellectis Inc.

Via GlobeNewswire

Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update

November 07, 2025

From Cellectis Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Cellectis S.A. - American Depositary Shares publicly traded?

Yes, Cellectis S.A. - American Depositary Shares is publicly traded.

What exchange does Cellectis S.A. - American Depositary Shares trade on?

Cellectis S.A. - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Cellectis S.A. - American Depositary Shares?

The ticker symbol for Cellectis S.A. - American Depositary Shares is CLLS on the Nasdaq Stock Market

What is the current price of Cellectis S.A. - American Depositary Shares?

The current price of Cellectis S.A. - American Depositary Shares is 3.420

When was Cellectis S.A. - American Depositary Shares last traded?

The last trade of Cellectis S.A. - American Depositary Shares was at 08/26/26 10:04 AM ET

What is the market capitalization of Cellectis S.A. - American Depositary Shares?

The market capitalization of Cellectis S.A. - American Depositary Shares is 155.56M

How many shares of Cellectis S.A. - American Depositary Shares are outstanding?

Cellectis S.A. - American Depositary Shares has 156M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.